Connect your AI

Evolus EOLS Convertible Preferred Stock Outstanding Shares

Convertible Preferred Stock Outstanding Shares at other companies

CelcuityCELC

0-100%

Lesaka Technologies, Inc.LSAK

0—

Rigel PharmaceuticalsRIGL

0—

Edgewell Personal CareEPC

0—

New America Acquisition I NWAX

0—

ADMA BiologicsADMA

0—

Other financials

Income statement

Revenue$73.1M+6.7%

Gross profit$48.9M+4.8%

Operating income-$6.8M+54.9%

Net income-$10.7M+43.5%

EPS (diluted)-$0.16+46.7%

Balance sheet

Cash & equivalents$49.8M-26.7%

Total debt$164.9M-4.1%

Total equity-$28.8M-336%

Total assets$220.6M+3.4%

Cash flow

Operating cash flow-$10.0M+36.3%

CapEx$415.0K+30.1%

Free cash flow-$10.4M+35.0%

Valuation

Market cap$470.86M-21.3%

Enterprise value$585.97M-16.6%

P/S1.6×-0.6×

Profitability

Gross margin66.1%-2.4pp

Operating margin-13.7%-1.9pp

Net margin-14.4%-3.3pp

FCF margin-9.6%-3.6pp

Returns & leverage

Return on equity-472.6%-1,534pp

Debt / equity22.2×—

Current ratio2×-0.3×

Where this comes from

Reported directly by Evolus in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesOutstanding.

The official record: Evolus’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evolus's convertible preferred stock outstanding shares.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Evolus's convertible preferred stock outstanding shares?: Evolus (EOLS) reported convertible preferred stock outstanding shares of 0 in Q1 2026.